Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fampridine Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00053417
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 25, 2026, 6:08 AM EDT
Completed No phase listed Observational Results available

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

NCT01535664
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Withdrawal of dalfampridine-ER 10mg
Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

NCT00648908
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 25, 2026, 6:08 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

NCT02422940
View directory record Official record
Conditions
Post-ischemic Stroke
Interventions
dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
62
States / cities
Gilbert, Arizona • Berkeley, California • Carlsbad, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 1 Interventional

Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA

NCT05769478
View directory record Official record
Conditions
Botulism, Iatrogenic Botulism
Interventions
Amifampridine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Study of Oral Fampridine-SR in Multiple Sclerosis

NCT00127530
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 25, 2026, 6:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

NCT06853015
View directory record Official record
Conditions
SCI - Spinal Cord Injury
Interventions
Dalfampridine, Placebo, STDP stimulation, Exercise training
Drug · Other · Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 6:08 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
Interventions
Amifampridine Phosphate
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

NCT01511978
View directory record Official record
Conditions
Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Interventions
Continuous 3,4-DAP, Taper 3,4-DAP to Placebo
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
7
States / cities
Sacramento, California • Indianapolis, Indiana • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

NCT00649792
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
38
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 25, 2026, 6:08 AM EDT
No Longer Available No phase listed Expanded access

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

NCT01378546
View directory record Official record
Conditions
Lambert Eaton Myasthenic Syndrome (LEMS)
Interventions
3,4-diaminopyridine
Drug
Lead sponsor
Louis H. Weimer, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 4 Interventional

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT01975324
View directory record Official record
Conditions
Non Arteritic Ischemic Optic Neuropathy
Interventions
dalfampridine, Placebo
Drug
Lead sponsor
Neuro-Ophthalmologic Associates, PC
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ampyra for Optic Neuritis in Multiple Sclerosis

NCT01337986
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis
Interventions
Dalfampridine/Placebo, Placebo/Dalfampridine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT01683838
View directory record Official record
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 25, 2026, 6:08 AM EDT
Recruiting Phase 1 Interventional

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

NCT07171203
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib, Fampridine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

NCT01605825
View directory record Official record
Conditions
Ischemic Stroke
Interventions
placebo/dalfampridine-ER, dalfampridine-ER/placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Birmingham, Alabama • La Jolla, California • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

NCT00483652
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 25, 2026, 6:08 AM EDT
Recruiting Phase 2 Interventional

4-AP Peripheral Nerve Crossover Trial

NCT06003166
View directory record Official record
Conditions
Peripheral Nerve Injury, Crush Injury
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

NCT02562066
View directory record Official record
Conditions
Myasthenic Syndromes, Congenital
Interventions
amifampridine phosphate, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 2 Interventional

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

NCT01621113
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 25, 2026, 6:08 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

4-aminopyridine for Skin Wound Healing

NCT06333171
View directory record Official record
Conditions
Wounds, Wound of Skin, Wound Heal, Wounds and Injuries
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

NCT01468350
View directory record Official record
Conditions
Cerebral Palsy (CP)
Interventions
dalfampridine-ER 10mg, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 25, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Results available

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

NCT02391961
View directory record Official record
Conditions
Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 25, 2026, 6:08 AM EDT